Skip to Content

Beta Bionics announces IPO pricing

Beta Bionics announces IPO pricing

IRVINE, Calif. – Beta Bionics has announced the pricing of its upsized initial public offering of 12 million shares of common stock at a price to the public of $17 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and offering expenses are expected to be $204 million. In addition, the underwriters have a 30-day option to purchase up to an additional 1.8 million shares of common stock at the public offering price, less underwriting discounts and commissions, consisting of 475,000 shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus. Beta Bionics will not receive any proceeds from any sale of shares by the selling stockholders. The shares are expected to begin trading on the Nasdaq Global Market on Jan. 30, 2025, under the ticker symbol “BBNX.” The offering is expected to close on Jan. 31, 2025, subject to the satisfaction of customary closing conditions. BofA Securities, Piper Sandler and Leerink Partners are acting as lead bookrunners for the proposed offering. Stifel is acting as a bookrunner and Lake Street Capital Markets is acting as co-manager for the offering.  

Comments

To comment on this post, please log in to your account or set up an account now.